Merck Zocor Rhabdomyolysis Risk Is Dose-Related, Revised Warning Says
Executive Summary
The risk of myopathy and rhabdomyolysis associated with Merck's Zocor (simvastatin) increases in proportion to the dose, revised labeling says
You may also be interested in...
Schering-Plough Zetia Could Be More Important Growth Product Than Claritin
Schering-Plough's cholesterol agent Zetia could be an even larger growth driver than Claritin, CEO Richard Kogan told analysts at the company's annual meeting on July 16
Schering-Plough Zetia Could Be More Important Growth Product Than Claritin
Schering-Plough's cholesterol agent Zetia could be an even larger growth driver than Claritin, CEO Richard Kogan told analysts at the company's annual meeting on July 16
AstraZeneca Crestor 80 Mg Dose Would Have Low Demand, CEO Suggests
AstraZeneca expects that an 80 mg strength of Crestor, if approved, would constitute a small proportion of the product's sales